Ion Beam Applications, SA

Delisting Announcement • Dec 14, 2015

Full disposal of IBA Molecular by IBA S.A.

Louvain-la-Neuve, Belgium – 14 December 2015 - IBA (Ion Beam Applications S.A.) the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a definitive agreement for the sale of IBA Molecular ("IBAM"), in which IBA has a 40% stake, to funds advised by CapVest Partners LP ("CapVest"). IBAM is a joint-venture jointly owned by IBA (40%) and SK Capital Partners (60%).

This transaction is estimated to be worth circa EUR 55 million to IBA in cash, representing a capital gain of circa EUR 30 million based on the current valuation in IBA's books and is subject to customary closing conditions. The closing of the transaction is expected by the end of the first quarter of 2016.

As a reminder, in August, IBA also announced that the US activities of IBAM had been acquired by Illinois Health and Science. Today's transaction concerns the remainder of the IBAM business and its closing will complete IBA's exit from this business.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are pleased to have completed, together with SK Capital Partners, the disposal of the assets of IBA Molecular in line with our strategy to divest non-core assets in order to focus IBA on proton therapy and associated technologies. We are confident that CapVest is the ideal acquirer of IBA Molecular and that it will take the Company to the next level in its development."

***END***

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Press release |

Regulated information

About CapVest

CapVest is an established European mid-market private equity firm focused on acquiring market leading companies supplying essential products and services. The firm places an emphasis on driving business growth through active management and has demonstrated consistent success in creating long-term value. For more information, visit www.capvest.co.uk

For further information please contact:

IBA Jean-Marc Bothy Chief Financial Officer Tel: +32 10 47 58 90

Thomas Ralet

Vice-President Corporate Communication +32 10 47 58 90 communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications Amber Bielecka, Matthew Neal, Jessica Hodgson and Ivar Milligan +44 (0)20 3709 5700 IBA@consilium-comms.com

Rx Communications Group (US) Melody Carey + 1 917 322 2571 mcarey@RxIR.com

Press release | 14 December 2015 2 | 2